These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

666 related articles for article (PubMed ID: 22551029)

  • 1. Review of the risks and benefits of yellow fever vaccination including some new analyses.
    Monath TP
    Expert Rev Vaccines; 2012 Apr; 11(4):427-48. PubMed ID: 22551029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of yellow fever in persons traveling to the tropics.
    Monath TP; Cetron MS
    Clin Infect Dis; 2002 May; 34(10):1369-78. PubMed ID: 11981733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Staples JE; Gershman M; Fischer M;
    MMWR Recomm Rep; 2010 Jul; 59(RR-7):1-27. PubMed ID: 20671663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A case suspected for yellow fever vaccine-associated viscerotropic disease in the Netherlands.
    van de Pol EM; Gisolf EH; Richter C
    J Travel Med; 2014; 21(6):421-4. PubMed ID: 24920138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Yellow fever].
    Wiercińska-Drapało A
    Przegl Epidemiol; 2004; 58 Suppl 1():101-5. PubMed ID: 15807166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010.
    Breugelmans JG; Lewis RF; Agbenu E; Veit O; Jackson D; Domingo C; Böthe M; Perea W; Niedrig M; Gessner BD; Yactayo S;
    Vaccine; 2013 Apr; 31(14):1819-29. PubMed ID: 23395587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Viscerotropic disease following yellow fever vaccination in Peru.
    Whittembury A; Ramirez G; Hernández H; Ropero AM; Waterman S; Ticona M; Brinton M; Uchuya J; Gershman M; Toledo W; Staples E; Campos C; Martínez M; Chang GJ; Cabezas C; Lanciotti R; Zaki S; Montgomery JM; Monath T; Hayes E
    Vaccine; 2009 Oct; 27(43):5974-81. PubMed ID: 19679215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of yellow fever vaccine-associated viscerotropic disease among the elderly: a systematic review.
    Rafferty E; Duclos P; Yactayo S; Schuster M
    Vaccine; 2013 Dec; 31(49):5798-805. PubMed ID: 24079979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune response during adverse events after 17D-derived yellow fever vaccination in Europe.
    Bae HG; Domingo C; Tenorio A; de Ory F; Muñoz J; Weber P; Teuwen DE; Niedrig M
    J Infect Dis; 2008 Jun; 197(11):1577-84. PubMed ID: 18419548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse event reports following yellow fever vaccination.
    Lindsey NP; Schroeder BA; Miller ER; Braun MM; Hinckley AF; Marano N; Slade BA; Barnett ED; Brunette GW; Horan K; Staples JE; Kozarsky PE; Hayes EB
    Vaccine; 2008 Nov; 26(48):6077-82. PubMed ID: 18809449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Yellow fever vaccine: an effective vaccine for travelers.
    Verma R; Khanna P; Chawla S
    Hum Vaccin Immunother; 2014; 10(1):126-8. PubMed ID: 24056028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Yellow fever-associated viscerotropic disease in Barcelona, Spain.
    Muñoz J; Vilella A; Domingo C; Nicolas JM; de Ory F; Corachan M; Tenorio A; Gascon J
    J Travel Med; 2008; 15(3):202-5. PubMed ID: 18494699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse events associated with 17D-derived yellow fever vaccination--United States, 2001-2002.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2002 Nov; 51(44):989-93. PubMed ID: 12455906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Yellow fever: epidemiology and prevention.
    Barnett ED
    Clin Infect Dis; 2007 Mar; 44(6):850-6. PubMed ID: 17304460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse event reports following yellow fever vaccination, 2007-13.
    Lindsey NP; Rabe IB; Miller ER; Fischer M; Staples JE
    J Travel Med; 2016 May; 23(5):. PubMed ID: 27378369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Yellow fever vaccine: worthy friend or stealthy foe?
    Seligman SJ; Casanova JL
    Expert Rev Vaccines; 2016 Jun; 15(6):681-91. PubMed ID: 27087465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First case of yellow fever vaccine-associated viscerotropic disease (YEL-AVD) in Hong Kong.
    Leung WS; Chan MC; Chik SH; Tsang TY
    J Travel Med; 2016 Apr; 23(4):. PubMed ID: 27087559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Yellow fever vaccination: update on rare and severe adverse effects].
    Receveur MC; Bruyand M; Pistone T; Malvy D
    Med Mal Infect; 2009 Apr; 39(4):234-41. PubMed ID: 19167852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Yellow fever vaccines and international travelers.
    Barnett ED; Wilder-Smith A; Wilson ME
    Expert Rev Vaccines; 2008 Jul; 7(5):579-87. PubMed ID: 18564013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Yellow fever vaccine usage in the United States and risk of neurotropic and viscerotropic disease: A retrospective cohort study using three healthcare databases.
    Ledlie S; Ricci C; Pan C; Rojas A; Khromava A; Li L
    Vaccine; 2022 Jan; 40(5):742-751. PubMed ID: 34996642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.